IMAGE: Lung adenocarcinoma cells with high level of autophagy. view more
Credit: Courtesy of Boris Zhivotovsky.
During carcinogenesis malignant cells undergo uncontrolled division, causing the tumor dissemination. Target therapy is an actively developing area of cancer treatment. It includes blocking the action of certain proteins that are essential for controlling of tumor growth or activating non-functional proteins that control cell division. One of these proteins is a tumor suppressor (antioncogenic) protein p53 that is mutated in about 50% of all tumors. Using several new compounds it is possible to increase the activity of wild type p53. Some other compounds are able to reactivate mutated p53, making it more active and able to participate in the cancer cell suicide. These attempts are expected to be more efficient and less harmful for healthy cells.
The p53 tumor suppressor protein also known as “the guardian of the genome”, supports the genetic stability of the cells and prevents the occurrence of malignant tumors. The protein is activated in response to damage of the genetic material, accumulated to a particular level, bound to the certain DNA regions and blocks the replication and the growth of “damaged” cells.
A team of researchers from MSU together
Article originally posted at